OCUGEN, INC. Total Liabilities
OCUGEN, INC. (OCGN) had Total Liabilities of $140.76 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-06
- 2026-06-30: Liabilities $140.76M.
- 2026-03-31: Liabilities $51.10M.
- 2025-12-31: Liabilities $55.68M.
- 2025-09-30: Liabilities $54.06M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $140.76M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $51.10M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $55.68M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $54.06M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $50.54M 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $48.55M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $52.81M 10-K · filed 2026-03-04 | |
| 2024-09-30 | $21.31M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $23.61M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $21.53M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $23.98M 10-K · filed 2025-03-05 | |
| 2023-09-30 | $24.89M 10-K · filed 2024-04-16 | $16.29M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $29.73M 10-K · filed 2024-04-16 | $18.70M 10-Q · filed 2023-08-21 |
| 2023-03-31 | $31.40M 10-K · filed 2024-04-16 | $20.50M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $34.65M 10-K · filed 2024-04-16 | $24.58M 10-K · filed 2023-02-28 |
| 2022-09-30 | $30.55M 10-K · filed 2024-04-16 | $20.94M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $23.61M 10-K · filed 2024-04-16 | $15.98M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $16.21M 10-K · filed 2024-04-16 | $10.60M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $9.94M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $9.20M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $7.84M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $7.36M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $5.83M 10-K · filed 2022-02-28 | $5.83M 10-K · filed 2021-03-19 |
| 2020-09-30 | $6.12M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $9.14M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $5.02M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $5.79M 10-K · filed 2021-03-19 | |
| 2019-09-30 | $36.71M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $10.23M 8-K/A · filed 2019-10-07 | $11.93M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $20.37M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $15.16M 10-K · filed 2020-03-27 | $17.89M 10-K · filed 2019-03-22 |
| 2018-09-30 | $20.56M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $38.59M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $41.40M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $22.30M 10-K · filed 2019-03-22 | |
| 2017-09-30 | $20.64M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $21.32M 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $21.34M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $22.51M 10-K · filed 2018-03-15 | |
| 2016-09-30 | $38.76M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $8.39M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $7.92M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $8.59M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $9.13M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $9.37M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $10.36M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $11.29M 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |